Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must be Japanese as determined by participant's verbal report~* Must be healthy or medically stable, in the investigator's clinical judgment, as confirmed by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests performed at the screening visit~* Willing and able to adhere to the lifestyle restrictions~* Agrees not to donate blood until 12 weeks after receiving the study intervention~* Must be willing to provide verifiable identification, has means to be contacted, and to contact the investigator during the study~Exclusion Criteria:~* Clinically significant illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature greater than or equal to (\>=) 38.0 degree Celsius (100.4 degree Fahrenheit ) within 24 hours prior to the administration of study intervention; enrollment at a later date is permitted (provided the screening window of 28 days is respected)~* History of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)~* Known allergies, hypersensitivity, or intolerance to ExPEC10V or its excipients~* Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine excipients~* Contraindication to Intramuscular (IM) injections and blood draws example, bleeding disorders

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Medium-dose ExPEC10V or Placebo: Group 1 (Type: EXPERIMENTAL): Participants will be randomized to receive a single intramuscular (IM) injection of medium dose of ExPEC10V or Placebo on Day 1.
- High-dose ExPEC10V or Placebo: Group 2 (Type: EXPERIMENTAL): Participants will be randomized to receive a single IM injection of high dose (based on safety assessment through Day 15 postvaccination of medium dose) of ExPEC10V or Placebo on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).